BioMedNewsBreaks

WednesdayApr 10, 2024 9:15 am

BioMedNewsBreaks — Telo Genomics Corp. (TSX.V: TELO) (OTCQB: TDSGF) Notes Key Milestone with Award of College of American Pathologists Accreditation

Telo Genomics (TSX.V: TELO) (OTCQB: TDSGF),a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, has received accreditation for its Toronto-based laboratory at the MaRS Center from the Accreditation Committee of the College of American Pathologists (“CAP”). The accreditation followed more than a year of preparation and an on-site inspection by the CAP Accreditation Programs. CAP is the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, and its accreditation recognizes rigorous and robust standards. “The CAP accreditation highlights Telo Genomics' commitment and…

Continue Reading

TuesdayApr 09, 2024 4:12 pm

BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Adds AI Expert to Support Development of Phase 2 Clinical Trial

IGC Pharma (NYSE American: IGC), a company focused on developing innovative solutions to address Alzheimer’s disease, has announced the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world’s top researchers. Dr. Arbelaez will support the development of the Phase 2 clinical trial of IGC Pharma’s lead therapeutic candidate IGC-AD1, targeting agitation in Alzheimer’s. “We welcome Dr. Pablo Arbelaez to our team of senior advisors. His expertise in AI will aid in enhancing early detection methods for Alzheimer’s disease and subsequently aiding faster diagnoses, which is essential for effective treatment,” said Ram Mukunda, CEO…

Continue Reading

TuesdayApr 09, 2024 3:36 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Presents Key Data in First-Ever Scientific Presentation of Proprietary HeartBeam AI

HeartBeam(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, is presenting new data at the European Heart Rhythm Association (“EHRA”) Conference. According to the announcement, this is the first scientific presentation on the company’s deep learning algorithm: HeartBeam AI. The data demonstrates that applying the company’s artificial intelligence (“AI”) algorithms to vectorcardiography (“VCG”) showed considerably improved performance in the detection of atrial flutter over single-lead electrocardiograms (“ECGs”) and similar performance to 12-lead ECGs, the standard for diagnosing atrial flutter. The company noted that the data indicates an opportunity for a VCG-based algorithm…

Continue Reading

MondayApr 08, 2024 2:43 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), Scinai Bioservices Enter MSA with Ayana Pharma

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products, through its contract development and manufacturing organization (“CDMO”) business unit, Scinai Bioservices, has signed a five-year Master Service Agreement (“MSA”) with Ayana Pharma Ltd. As outlined by the MSA, Scinai will provide drug-development and cGMP manufacturing services to Ayana; the agreement is forecast to bring in at least $1.8 million in revenues for Scinai over the next five years. Ayana officials noted that the company had done an extensive search looking for a CDMO and was “attracted” to Scinai’s experience in biopharmaceutical drug development and manufacturing for…

Continue Reading

FridayApr 05, 2024 12:23 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Developing Robust Product Lineup to Address ASD, Associated Neurodevelopmental Conditions

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. The company is on a promising path to address the unmet medical needs of ASD, bringing hope to millions. “ASD is a developmental disorder affecting how individuals interact with other people, behavior, communication, and learning. This disorder can be diagnosed at any age, but symptoms often appear in the first two years of life. There is currently no approved pharmacologic treatment targeting the cause and symptoms. Current…

Continue Reading

TuesdayApr 02, 2024 3:10 pm

BioMedNewsBreaks – Astrotech Corp. (NASDAQ: ASTC), Subsidiary Set to Spotlight Tracer 1000 Trace Detector at Leading Security Trade Event

Astrotech (NASDAQ: ASTC), an innovative science and technology company, and its wholly owned subsidiary, 1st Detect Corporation, will be showcasing the TRACER 1000 Narcotics Trace Detector (“NTD”) and Explosives Trace Detector (“ETD”) at the International Security Conference and Exposition. Known as ISC West, the conference and expo is slated to run April 9–12, 2024, in Las Vegas; the event is the one of the leading comprehensive security trade events in the nation and will be attended by key security and public-safety professionals. A high-performance laboratory instrument powered by Astrotech Mass Spectrometer Technology(TM), the TRACER 1000 can detect trace levels of narcotics…

Continue Reading

TuesdayApr 02, 2024 1:45 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizing Genprex’s non-viral Oncoprex(R) Delivery System, in KRAS/STK11 mutant anti-PD1 resistant non-small cell lung cancer (“NSCLC”) in a humanized mouse model. “These positive preclinical data are very encouraging and support NPRL2 gene therapy as a potential treatment for a sub-group of NSCLC in which patients traditionally are resistant to existing therapies,” said Rodney Varner, president, chairman and CEO at Genprex. “We…

Continue Reading

TuesdayApr 02, 2024 1:10 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released financial results for the full year ending Dec. 31, 2023; the company also reported on corporate and clinical development achievement for the year. Highlights of the report included that Berubicin, the company’s lead program, has passed preplanned interim futility analysis milestones with a recommendation to proceed without modification into a potentially pivotal glioblastoma multiforme (“GBM”) study, and enrollment for the Berubicin study has been completed with topline data expected in first half…

Continue Reading

TuesdayApr 02, 2024 11:45 am

BioMedNewsBreaks — Astiva Health Setting New Standard for Patient-Centric Care

Astiva Health, a leading provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, is championing a model of care that emphasizes proactive health management and a healthy lifestyle over traditional reactive methods. “At the core of Astiva Health’s innovative approach is the principle of patient-centric care. This method prioritizes the active involvement of patients in their healthcare decisions, ensuring their preferences, needs and values guide their care plans… A critical element in Astiva Health’s strategy is the development of a supportive health community. This community – encompassing healthcare professionals, family, caregivers, and peer groups – provides…

Continue Reading

MondayApr 01, 2024 3:31 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Releases Year-End 2023 Financial Report, Business Update

  Predictive Oncology (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial-intelligence (“AI”) and machine-learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to accelerate oncologic drug discovery and enable drug development, is reporting on its financial and operating results for the year ended Dec. 31, 2023; the company also released a corporate update. The report noted POAI experienced a net loss of some $14 million on total revenue of approximately $1.8 million for the year; the company also reported a 50% reduction in basic and diluted net loss per common share for the full year 2023.…

Continue Reading